Literature DB >> 16121701

The potential impact of hypoxia on the success of oncolytic virotherapy.

John G Hay1.   

Abstract

The biological properties of oncolytic viruses, in particular the ability to replicate within a tumor cell and then spread from cell to cell are highly desirable features for cancer therapy. However. several features of the tumor environment may not be conducive for efficient viral spread. Hypoxia is an important feature of solid tumors and the ability of viruses to replicate in hypoxic conditions may be a critical determinant in the success or failure of virotherapy. Turning off protein translation is a central process in the cellular adaptation to many types of stress, including viral infection and hypoxia. How a specific virus has evolved to overcome the cellular mechanisms that regulate translation in the cell under stress may be critical for the success of virotherapy.

Entities:  

Mesh:

Year:  2005        PMID: 16121701

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN: 1464-8431


  7 in total

1.  Cyclophosphamide increases transgene expression mediated by an oncolytic adenovirus in glioma-bearing mice monitored by bioluminescence imaging.

Authors:  Martine L M Lamfers; Giulia Fulci; Davide Gianni; Yi Tang; Kazuhiko Kurozumi; Balveen Kaur; Sharif Moeniralm; Yoshinaga Saeki; Jan E Carette; Ralph Weissleder; W Peter Vandertop; Victor W van Beusechem; Clemens M F Dirven; E Antonio Chiocca
Journal:  Mol Ther       Date:  2006-09-22       Impact factor: 11.454

2.  Phosphorylation of cAMP response element binding protein (CREB) as a marker of hypoxia in pituitary adenoma.

Authors:  Daijiro Morimoto; Daizo Yoshida; Masahiro Noha; Masanori Suzuki; R Yoshiyuki Osamura; Akira Teramoto
Journal:  J Neurooncol       Date:  2006-04-06       Impact factor: 4.130

Review 3.  Design and application of oncolytic HSV vectors for glioblastoma therapy.

Authors:  Paola Grandi; Pierpaolo Peruzzi; Bonnie Reinhart; Justus B Cohen; E Antonio Chiocca; Joseph C Glorioso
Journal:  Expert Rev Neurother       Date:  2009-04       Impact factor: 4.618

Review 4.  Pharmacologic and chemical adjuvants in tumor virotherapy.

Authors:  Christopher Alvarez-Breckenridge; Balveen Kaur; E Antonio Chiocca
Journal:  Chem Rev       Date:  2009-07       Impact factor: 60.622

Review 5.  Oncolytic Virotherapy versus Cancer Stem Cells: A Review of Approaches and Mechanisms.

Authors:  Shyambabu Chaurasiya; Nanhai G Chen; Susanne G Warner
Journal:  Cancers (Basel)       Date:  2018-04-19       Impact factor: 6.639

6.  Lister strain vaccinia virus, a potential therapeutic vector targeting hypoxic tumours.

Authors:  C T Hiley; M Yuan; N R Lemoine; Y Wang
Journal:  Gene Ther       Date:  2009-11-05       Impact factor: 5.250

7.  Clostridial spores as live 'Trojan horse' vectors for cancer gene therapy: comparison with viral delivery systems.

Authors:  Ming Q Wei; Ruimei Ren; David Good; Jozef Anné
Journal:  Genet Vaccines Ther       Date:  2008-02-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.